Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs).

Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs). Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs). Abstract Text:

Joseph A Blansfield,Lynda Choyke,Shane Y Morita,Peter L Choyke,James F Pingpank,H Richard Alexander,Geoffrey Seidel,Yvonne Shutack,Nargiza Yuldasheva,Michelle Eugeni,David L Bartlett,Gladys M Glenn,Lindsay Middelton,W Marston Linehan,Steven K Libutti,Joseph A Blansfield,Lynda Choyke,Shane Y Morita,Peter L Choyke,James F Pingpank,H Richard Alexander,Geoffrey Seidel,Yvonne Shutack,Nargiza Yuldasheva,Michelle Eugeni,David L Bartlett,Gladys M Glenn,Lindsay Middelton,W Marston Linehan,Steven K Libutti,Joseph A Blansfield,Lynda Choyke,Shane Y Morita,Peter L Choyke,James F Pingpank,H Richard Alexander,Geoffrey Seidel,Yvonne Shutack,Nargiza Yuldasheva,Michelle Eugeni,David L Bartlett,Gladys M Glenn,Lindsay Middelton,W Marston Linehan,Steven K Libutti,

BACKGROUND: von Hippel-Lindau (vHL) disease is an autosomal dominant syndrome associated with neoplasms in multiple organs, which includes the pancreas. Here, we report the greatest single center experience in patients with vHL pancreatic endocrine neoplasm (PNETs). METHODS: Between December 1998 and November 2006, 633 patients with vHL were evaluated and those with PNETs were enrolled on a prospective protocol. RESULTS: Overall, 108 vHL patients had PNETs (17%). Nine patients had metastatic disease (8.3%) from their PNET. Patients with lesions greater than 3 cm (n = 25) were more likely to develop metastases than patients with lesions less than 3 cm (n = 83) (P < .005). Thirty-nine patients underwent resection. Germline sequencing showed that 78% of patients with metastases (7/9) had exon 3 mutations compared with 46% of patients without metastases (32/98; P < .01). Tumor doubling time was calculated for the largest PNET. The group with metastases had an average tumor doubling time of 337 days (range, 180-463 days) compared with 2630 days (range, 103-9614 days) for those without metastases (P < .0001). CONCLUSIONS: By implementing a system of selective operative resection based on defined criteria, vHL patients with PNETs can be managed safely. For patients with small primary lesions (<3 cm), without a mutation of exon 3 and slow tumor doubling time (>500 days), a nonoperative approach may be appropriate for these nonfunctional neoplasms.

Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs). Publishing Authors By Initials

JA Blansfield,L Choyke,SY Morita,PL Choyke,JF Pingpank,HR Alexander,G Seidel,Y Shutack,N Yuldasheva,M Eugeni,DL Bartlett,GM Glenn,L Middelton,WM Linehan,SK Libutti,JA Blansfield,L Choyke,SY Morita,PL Choyke,JF Pingpank,HR Alexander,G Seidel,Y Shutack,N Yuldasheva,M Eugeni,DL Bartlett,GM Glenn,L Middelton,WM Linehan,SK Libutti,JA Blansfield,L Choyke,SY Morita,PL Choyke,JF Pingpank,HR Alexander,G Seidel,Y Shutack,N Yuldasheva,M Eugeni,DL Bartlett,GM Glenn,L Middelton,WM Linehan,SK Libutti,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs). Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Surgery

VOLUME: 142

Page Numbers: 814-8

Journal Abbreviation: Surgery

ISSN: 1532-7361

DAY: 7

MONTH: Dec

YEAR: 2007

Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs). Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 417347

Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs). Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs). Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs).

AFFILIATION: Tumor Angiogenesis Section, Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Md. 20892, USA.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Surgery

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease VHL manifested by pancreatic neuroendocrine neoplasms PNETs Related Publications

• Antiangiogenic gene therapy of cancer utilizing a recombinant adenovirus to elevate systemic endostatin levels in mice.
• Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs).
• Combining Agents that Target the Tumor Microenvironment Improves the Efficacy of Anticancer Therapy.
• Functional characterization of filamin a interacting protein 1-like, a novel candidate for antivascular cancer therapy.
• Operative management of Cushing syndrome secondary to micronodular adrenal hyperplasia.
• Report from the society for biological therapy and vascular biology faculty of the NCI workshop on angiogenesis monitoring.
• Tumor angiogenesis and endothelial cell modulatory factors.